![Marty Freed](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marty Freed
Direktor/Vorstandsmitglied bei Avilar Therapeutics, Inc.
Ursprung des Netzwerks ersten Grades von Marty Freed
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Avilar Therapeutics, Inc.
![]() Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Marty Freed
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
RA Capital Management LP (Private Equity)
![]() RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor Private Equity Analyst Corporate Officer/Principal | |
ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Medical Microinstruments SpA
![]() Medical Microinstruments SpA Medical SpecialtiesHealth Technology Medical Microinstruments SpA develops and manufactures surgical micro-instruments. The firm focuses on clinical outcomes for patients undergoing microsurgery, and offers advanced microsurgical procedures, while reducing costs for patients, hospitals and for society at large. The company was founded by Giuseppe Prisco, Hannah Teichmann and Massimiliano Simi in 2015 and is headquartered in Calci, Italy. | Medical Specialties | Director/Board Member | |
Tilos Therapeutics, Inc.
![]() Tilos Therapeutics, Inc. BiotechnologyHealth Technology Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
University of Notre Dame | College/University | Doctorate Degree | |
Hillsdale College | College/University | Undergraduate Degree | |
Boehringer Ingelheim Venture Fund
![]() Boehringer Ingelheim Venture Fund Investment ManagersFinance Boehringer Ingelheim Venture Fund is an evergreen venture capital fund which seeks investment opportunities in biotech across the globe. It targets investments unrelated to Boehringer Ingelheim’s key therapeutic areas. Specifically, it focuses on start-up companies engaging in patient care enhancements through pioneering science including new therapeutic platforms, new generation vaccines, and new generation protein & antibody technologies, among others. The fund makes initial equity investments of EUR 500 thousand to EUR 3 million in seed or series A rounds. It also makes follow-on investments over a five to seven year time period, bringing the total investment size per company to an amount of EUR 10 million to EUR 15 million. The fund seeks to acquire minority stakes (usually greater than or equal to 10%) in target companies, as well as a seat on the board. | Investment Managers | Private Equity Investor | |
University of Toronto | College/University | Undergraduate Degree | |
WAVE LIFE SCIENCES LTD. | Biotechnology | Director/Board Member | |
BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Enara Bio Ltd. | Biotechnology | Director/Board Member | |
CYTEK BIOSCIENCES, INC. | Medical Specialties | Director/Board Member | |
FOGHORN THERAPEUTICS INC. | Biotechnology | Corporate Officer/Principal | |
Nodexus, Inc.
![]() Nodexus, Inc. Miscellaneous Commercial ServicesCommercial Services Nodexus, Inc. operates as a biotechnology services platform. It provides research and diagnostics, drug discovery, cell line development, forensics, CRISPR, and animal vaccination. The company was founded by Karthik Balakrishnan and Anand Kesavarajuin 2014 and is headquartered in Hayward, CA. | Miscellaneous Commercial Services | Director/Board Member | |
RESEARCH ALLIANCE CORP. II | Financial Conglomerates | Director of Finance/CFO | |
Research Alliance Holdings II LLC | Corporate Officer/Principal | ||
COHBAR, INC. | Biotechnology | Director/Board Member | |
ReWind Therapeutics NV
![]() ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Pharmaceuticals: Major | Director/Board Member | |
Glyphic Biotechnologies Inc
![]() Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Chicago Biomedical Consortium | Consultant / Advisor | ||
SPERO THERAPEUTICS, INC. | Biotechnology | Founder | |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | ||
Boston University School of Medicine | College/University | Corporate Officer/Principal | |
Nayan Therapeutics, Inc.
![]() Nayan Therapeutics, Inc. BiotechnologyHealth Technology Nayan Therapeutics, Inc. operates as a biotechnology company. It focuses on small molecule development for oscular disorders involving rod degeneration. The company is headquartered in Medfield, MA. | Biotechnology | Chief Executive Officer | |
Santi Therapeutics, Inc.
![]() Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Clear Creek Bio, Inc.
![]() Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
The Ohio University
![]() The Ohio University Other Consumer ServicesConsumer Services Central Hockey League operates a professional minor league hockey teams playing in small to medium-sized markets primarily in central and southwestern US states. The league, which was started in 1992, is managed and operated by WPHL, a subsidiary of Global Entertainment Corporation. | College/University | Doctorate Degree | |
GentiBio, Inc.
![]() GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Biotechnology | Founder | |
Nivien Therapeutics Co.
![]() Nivien Therapeutics Co. Miscellaneous Commercial ServicesCommercial Services Nivien Therapeutics Co. is an American biotechnology company that operates in the field of biotechnology. The private company was founded by Nathaniel Brooks Horwitz. | Miscellaneous Commercial Services | Chief Executive Officer | |
Harvard University
![]() Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree | |
Superluminal Medicines Inc
![]() Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member | |
Omx Ventures LLC
![]() Omx Ventures LLC Investment ManagersFinance OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois. | Investment Managers | Private Equity Investor | |
ReAx Biotechnologies | Biotechnology | Director/Board Member | |
Seeker Biologics, Inc. | Director/Board Member | ||
Université Paris-Saclay | College/University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 30 |
Italien | 2 |
Deutschland | 2 |
Kanada | 2 |
Singapur | 2 |
Sektoral
Health Technology | 18 |
Consumer Services | 8 |
Finance | 5 |
Commercial Services | 5 |
Operativ
Director/Board Member | 24 |
Corporate Officer/Principal | 8 |
Chief Executive Officer | 7 |
President | 5 |
Founder | 5 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Jamie Kasuboski | 12 |
Milind Deshpande | 11 |
Tess Cameron | 11 |
NATHANIEL BROOKS HORWITZ | 7 |
Stephanie Tozzo | 3 |
Joshua Resnick | 1 |
- Börse
- Insiders
- Marty Freed
- Unternehmensverbindungen